Free Trial

KALA BIO (KALA) Competitors

KALA BIO logo
$5.28 +0.18 (+3.53%)
Closing price 04:00 PM Eastern
Extended Trading
$5.56 +0.29 (+5.40%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALA vs. FATE, PLX, NKTX, CRBU, ACTU, CRDL, ATOS, KRRO, VXRT, and GNLX

Should you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Nkarta (NKTX), Caribou Biosciences (CRBU), Actuate Therapeutics (ACTU), Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Korro Bio (KRRO), Vaxart (VXRT), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry.

KALA BIO vs. Its Competitors

Fate Therapeutics (NASDAQ:FATE) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

KALA BIO has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$13.63M8.91-$186.26M-$1.49-0.71
KALA BIO$3.89M8.75-$38.51M-$8.24-0.64

In the previous week, Fate Therapeutics had 6 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for Fate Therapeutics and 1 mentions for KALA BIO. Fate Therapeutics' average media sentiment score of 0.72 beat KALA BIO's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Fate Therapeutics presently has a consensus target price of $3.83, indicating a potential upside of 261.64%. KALA BIO has a consensus target price of $13.50, indicating a potential upside of 155.68%. Given Fate Therapeutics' higher probable upside, equities analysts plainly believe Fate Therapeutics is more favorable than KALA BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13
KALA BIO
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fate Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, meaning that its stock price is 288% less volatile than the S&P 500.

KALA BIO has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-1,318.93% -47.17% -34.60%
KALA BIO N/A -369.29%-64.99%

Summary

Fate Therapeutics beats KALA BIO on 10 of the 16 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KALA vs. The Competition

MetricKALA BIOMED IndustryMedical SectorNASDAQ Exchange
Market Cap$32.91M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.01%
P/E Ratio-0.647.5519.3119.89
Price / Sales8.75284.29424.59117.07
Price / CashN/A41.7026.2128.59
Price / Book2.617.397.925.55
Net Income-$38.51M-$55.04M$3.17B$248.49M
7 Day Performance10.92%3.01%2.18%5.37%
1 Month Performance27.54%-0.21%1.25%6.63%
1 Year Performance-23.48%4.48%33.90%21.20%

KALA BIO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KALA
KALA BIO
3.3634 of 5 stars
$5.28
+3.5%
$13.50
+155.7%
-23.3%$32.91M$3.89M-0.6430
FATE
Fate Therapeutics
4.2464 of 5 stars
$1.12
+7.7%
$3.83
+242.3%
-63.9%$119.19M$13.63M-0.75550Analyst Revision
Gap Up
PLX
Protalix BioTherapeutics
2.7297 of 5 stars
$1.48
-3.9%
$15.00
+913.5%
+47.1%$117.82M$59.76M-11.38200
NKTX
Nkarta
2.0729 of 5 stars
$1.66
flat
$14.33
+763.5%
-66.1%$117.79MN/A-1.10140
CRBU
Caribou Biosciences
2.0412 of 5 stars
$1.26
flat
$8.50
+574.6%
-15.0%$117.19M$9.99M-0.78100News Coverage
Analyst Upgrade
ACTU
Actuate Therapeutics
2.9841 of 5 stars
$6.11
+2.5%
$20.50
+235.5%
N/A$116.93MN/A0.0010High Trading Volume
CRDL
Cardiol Therapeutics
1.8743 of 5 stars
$1.36
-3.5%
$8.00
+488.2%
-23.4%$116.54MN/A-4.0020Upcoming Earnings
ATOS
Atossa Genetics
1.5704 of 5 stars
$0.83
-5.6%
$6.17
+643.0%
-24.1%$113.61MN/A-3.958
KRRO
Korro Bio
1.686 of 5 stars
$12.49
+3.8%
$102.43
+720.1%
-64.7%$112.97M$2.27M-1.3270Positive News
VXRT
Vaxart
2.2371 of 5 stars
$0.45
-8.6%
$3.00
+563.7%
-34.4%$112.90M$28.70M-1.67120Gap Down
GNLX
Genelux
1.9495 of 5 stars
$2.87
-4.0%
$17.75
+518.5%
+50.5%$112.83M$10K-3.2610News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:KALA) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners